Aratana Therapeutics Adds David Brinkley to Board of Directors

KANSAS CITY, Kan., March 27, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the appointment of former Theravance executive David L. Brinkley to its Board of Directors.  Mr. Brinkley's broad expertise spans business development, marketing, and animal health, for both mid- and large size biopharmaceutical companies.

Jay Lichter, Ph.D., Chairman of the Board of Aratana Therapeutics, stated, "We are pleased to welcome Mr. Brinkley to our Board, where he will also serve on the Compensation Committee.  We feel his specific combination of expertise and executive leadership is very well aligned with Aratana's business objectives.  We look forward to his many contributions, particularly as we transition to a commercial company, where his experience launching blockbuster products and building enduring brands will be invaluable."

Mr. Brinkley commented, "I am very excited to join Aratana as it continues to expand its footprint in the global pet therapeutics market.  I look forward to working with the talented team and to growing its leadership position and global brand in this emerging marketplace."

Mr. Brinkley worked for Theravance, Inc., from 2000 to 2013, serving most recently as the Head of Business Development. Mr. Brinkley served previously as Senior Vice President, Commercial Development at Theravance.  From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer through its acquisition of SmithKline Beecham's Animal Health operations, where he held various management positions from 1983 to 1995. Since July 2013, Mr. Brinkley has served as a director of Ziarco Pharma Ltd. He holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.

Aratana also announced that its Annual Meeting of Stockholders will be held on June 19, 2014, at 9:00 am Eastern time, at the offices of Latham & Watkins LLP, John Hancock Tower, 20th Floor, 200 Clarendon Street, Boston, Massachusetts 02116.  Holders of record at the close of business on April 23, 2014 will be entitled to vote at the meeting.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D.
[email protected]; (212) 375-2664

Andrew Mielach
[email protected]; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.